Gurpanna Saggu
Research Subjects
Gurpanna Saggu has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Allison Berger
Takeda Development Center Americas Inc., Lexington, Massachusetts
13 shared publications - Daniel P. Beiting
Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania
13 shared publications - Dmitry I. Gabrilovich
AstraZeneca, ICC, Early Oncology R&D, Gaithersburg, USA
13 shared publications - Fangxue Yan
Department of Biomedical Sciences, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
13 shared publications - Hongru Zhang
Department of Biomedical Sciences, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
13 shared publications - Jinyang Li
Department of Medicine, University of Pennsylvania
13 shared publications
Latest Publications
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Protection of Regulatory T Cells from Fragility and Inactivation in the Tumor Microenvironment
Supplementary Tables 1, 2, and 3
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from Protection of Regulatory T Cells from Fragility and Inactivation in the Tumor Microenvironment
Supplementary Tables 1, 2, and 3
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Protection of Regulatory T Cells from Fragility and Inactivation in the Tumor Microenvironment
Supplementary Figures 1-7 with legends
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Protection of Regulatory T Cells from Fragility and Inactivation in the Tumor Microenvironment
Supplementary Figures 1-7 with legends
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Protection of Regulatory T Cells from Fragility and Inactivation in the Tumor Microenvironment
Fragility of regulatory T (Treg) cells manifested by the loss of neuropilin-1 (NRP1) and expression of IFNγ undermines the immune suppressive functions of Treg cells and contributes to the success of immune therapies against cancers. Intratumoral Treg cells somehow avoid fragility; however, the mechanisms by which Treg cells are protected from fragility in the tumor microenvironment are not well understood. Here, we demonstrate that the IFNAR1 chain of the type I IFN (IFN1) receptor was downregulated on intratumoral Treg cells. Downregulation of IFNAR1 mediated by p38α kinase protected Treg cells from fragility and maintained NRP1 levels, which were decreased in response to IFN1. Genetic or pharmacologic inactivation of p38α and stabilization of IFNAR1 in Treg cells induced fragility and inhibited their immune suppressive and protumorigenic activities. The inhibitor of sumoylation TAK981 (Subasumstat) upregulated IFNAR1, eliciting Treg fragility and inhibiting tumor growth in an IFNAR1-dependent manner. These findings describe a mechanism by which intratumoral Treg cells retain immunosuppressive activities and suggest therapeutic approaches for inducing Treg fragility and increasing the efficacy of immunotherapies.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Protection of Regulatory T Cells from Fragility and Inactivation in the Tumor Microenvironment
Fragility of regulatory T (Treg) cells manifested by the loss of neuropilin-1 (NRP1) and expression of IFNγ undermines the immune suppressive functions of Treg cells and contributes to the success of immune therapies against cancers. Intratumoral Treg cells somehow avoid fragility; however, the mechanisms by which Treg cells are protected from fragility in the tumor microenvironment are not well understood. Here, we demonstrate that the IFNAR1 chain of the type I IFN (IFN1) receptor was downregulated on intratumoral Treg cells. Downregulation of IFNAR1 mediated by p38α kinase protected Treg cells from fragility and maintained NRP1 levels, which were decreased in response to IFN1. Genetic or pharmacologic inactivation of p38α and stabilization of IFNAR1 in Treg cells induced fragility and inhibited their immune suppressive and protumorigenic activities. The inhibitor of sumoylation TAK981 (Subasumstat) upregulated IFNAR1, eliciting Treg fragility and inhibiting tumor growth in an IFNAR1-dependent manner. These findings describe a mechanism by which intratumoral Treg cells retain immunosuppressive activities and suggest therapeutic approaches for inducing Treg fragility and increasing the efficacy of immunotherapies.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Protection of Regulatory T Cells from Fragility and Inactivation in the Tumor Microenvironment
Fragility of regulatory T (Treg) cells manifested by the loss of neuropilin-1 (NRP1) and expression of IFNγ undermines the immune suppressive functions of Treg cells and contributes to the success of immune therapies against cancers. Intratumoral Treg cells somehow avoid fragility; however, the mechanisms by which Treg cells are protected from fragility in the tumor microenvironment are not well understood. Here, we demonstrate that the IFNAR1 chain of the type I IFN (IFN1) receptor was downregulated on intratumoral Treg cells. Downregulation of IFNAR1 mediated by p38α kinase protected Treg cells from fragility and maintained NRP1 levels, which were decreased in response to IFN1. Genetic or pharmacologic inactivation of p38α and stabilization of IFNAR1 in Treg cells induced fragility and inhibited their immune suppressive and protumorigenic activities. The inhibitor of sumoylation TAK981 (Subasumstat) upregulated IFNAR1, eliciting Treg fragility and inhibiting tumor growth in an IFNAR1-dependent manner. These findings describe a mechanism by which intratumoral Treg cells retain immunosuppressive activities and suggest therapeutic approaches for inducing Treg fragility and increasing the efficacy of immunotherapies.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Protection of Regulatory T Cells from Fragility and Inactivation in the Tumor Microenvironment
Fragility of regulatory T (Treg) cells manifested by the loss of neuropilin-1 (NRP1) and expression of IFNγ undermines the immune suppressive functions of Treg cells and contributes to the success of immune therapies against cancers. Intratumoral Treg cells somehow avoid fragility; however, the mechanisms by which Treg cells are protected from fragility in the tumor microenvironment are not well understood. Here, we demonstrate that the IFNAR1 chain of the type I IFN (IFN1) receptor was downregulated on intratumoral Treg cells. Downregulation of IFNAR1 mediated by p38α kinase protected Treg cells from fragility and maintained NRP1 levels, which were decreased in response to IFN1. Genetic or pharmacologic inactivation of p38α and stabilization of IFNAR1 in Treg cells induced fragility and inhibited their immune suppressive and protumorigenic activities. The inhibitor of sumoylation TAK981 (Subasumstat) upregulated IFNAR1, eliciting Treg fragility and inhibiting tumor growth in an IFNAR1-dependent manner. These findings describe a mechanism by which intratumoral Treg cells retain immunosuppressive activities and suggest therapeutic approaches for inducing Treg fragility and increasing the efficacy of immunotherapies.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Protection of Regulatory T Cells from Fragility and Inactivation in the Tumor Microenvironment
Supplementary Figures 1-7 with legends
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Protection of Regulatory T Cells from Fragility and Inactivation in the Tumor Microenvironment
Supplementary Figures 1-7 with legends
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Protection of Regulatory T Cells from Fragility and Inactivation in the Tumor Microenvironment
Supplementary Data from Protection of Regulatory T Cells from Fragility and Inactivation in the Tumor Microenvironment
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Protection of Regulatory T Cells from Fragility and Inactivation in the Tumor Microenvironment
Supplementary Data from Protection of Regulatory T Cells from Fragility and Inactivation in the Tumor Microenvironment
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Protection of Regulatory T Cells from Fragility and Inactivation in the Tumor Microenvironment
Supplementary Data from Protection of Regulatory T Cells from Fragility and Inactivation in the Tumor Microenvironment
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Protection of Regulatory T Cells from Fragility and Inactivation in the Tumor Microenvironment
Supplementary Data from Protection of Regulatory T Cells from Fragility and Inactivation in the Tumor Microenvironment
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Protection of Regulatory T Cells from Fragility and Inactivation in the Tumor Microenvironment
Supplementary Figure from Protection of Regulatory T Cells from Fragility and Inactivation in the Tumor Microenvironment
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Protection of Regulatory T Cells from Fragility and Inactivation in the Tumor Microenvironment
Supplementary Figure from Protection of Regulatory T Cells from Fragility and Inactivation in the Tumor Microenvironment
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Protection of Regulatory T Cells from Fragility and Inactivation in the Tumor Microenvironment
Supplementary Tables 1, 2, and 3
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from Protection of Regulatory T Cells from Fragility and Inactivation in the Tumor Microenvironment
Supplementary Tables 1, 2, and 3
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Protection of Regulatory T Cells from Fragility and Inactivation in the Tumor Microenvironment
Supplementary Tables 1, 2, and 3
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from Protection of Regulatory T Cells from Fragility and Inactivation in the Tumor Microenvironment
Supplementary Tables 1, 2, and 3